TFIN vs DMRA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TFIN · Triumph Financial$61.23 ▼ 1.61%
DMRA · Damora Therapeutics$23.70 ▲ 8.42%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TFIN +14.3%
- DMRA +37.4%
Head to head
| Metric | TFIN | DMRA |
|---|---|---|
| Price | $61.23 | $23.70 |
| Change today | ▼ 1.61% | ▲ 8.42% |
| Market cap | $1.46B | $1.47B |
| Return, 3 months | -18.7% | -19.8% |
| Return, year to date | -2.2% | +3.0% |
| Return, 1 year | +13.7% | +378.8% |
| P/E (TTM) | 31.2 | 13.9 |
| P/B | 1.6 | 4.0 |
| P/E percentile vs own 5y | 36th | 4th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +14.4% | – |
| Net profit growth (YoY) | +686.2% | -807.0% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | 10.3% | – |
| Return on equity | 5.2% | -132.8% |
| Analyst target vs. price | +23.5% | +96.9% |
| Analyst buy share | 40% | 100% |
| RSI (14) | 43 | 60 |
| 30-day volatility | 25.1% | 58.4% |
| Max drawdown, 1 year | -26.0% | -46.9% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DMRA is the largest of the group by market value.
- DMRA has returned the most over the past year.
- DMRA carries the lowest trailing P/E.
- TFIN has been the calmest stock over the last 30 days.